rolipram has been researched along with Cancer-Associated Pain in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, CH | 1 |
| Bai, L | 1 |
| Wu, HH | 1 |
| Yang, J | 1 |
| Cai, GH | 1 |
| Wang, X | 1 |
| Wu, SX | 1 |
| Ma, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for rolipram and Cancer-Associated Pain
| Article | Year |
|---|---|
The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain.
Topics: Analgesics; Animals; Anthracenes; Astrocytes; Bone Neoplasms; Cancer Pain; Chemokine CCL2; Cyclic Nu | 2016 |